Urticae vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 344,799 | 376,307 | 362,833 | 298,131 | 247,881 | 218,850 | 193,216 | 166,129 |
| Profit before tax | 14,593 | 12,349 | 4,323 | -5,158 | 5,167 | -312 | -2,353 | -11,454 |
| Net profit | 13,936 | 11,793 | 4,128 | -5,158 | 5,167 | -312 | -2,353 | -11,454 |
| Equity | 85,817 | 98,166 | 102,489 | 97,330 | 102,497 | 102,185 | 99,832 | 88,378 |
| Liabilities | 135,899 | 152,297 | 123,000 | 109,753 | 99,582 | 83,164 | 70,756 | 62,172 |
| Non-current assets | 85,076 | 82,159 | 79,574 | 76,724 | 74,008 | 71,313 | 68,630 | 66,011 |
| Current assets | 136,640 | 168,304 | 145,915 | 130,359 | 128,071 | 114,036 | 101,958 | 84,539 |
| Total assets | 221,716 | 250,463 | 225,489 | 207,083 | 202,079 | 185,349 | 170,588 | 150,550 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 10,934 | 10,746 | 10,333 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +10.8% | +9.1% | -3.6% | -17.8% | -16.9% | -11.7% | -11.7% | -14.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 6.3% | 4.7% | 1.8% | -2.5% | 2.6% | -0.2% | -1.4% | -7.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 16.2% | 12.0% | 4.0% | -5.3% | 5.0% | -0.3% | -2.4% | -13.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.0% | 3.1% | 1.1% | -1.7% | 2.1% | -0.1% | -1.2% | -6.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 4.2% | 3.3% | 1.2% | -1.7% | 2.1% | -0.1% | -1.2% | -6.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.6 | 1.6 | 1.2 | 1.1 | 1.0 | 0.8 | 0.7 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 38,311 | 46,554 | 52,458 | 55,900 | 64,665 | 72,950 | 64,405 | 55,376 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Urticae vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-11-21 | 2022-12-13 | 0.11 |
| 2022-11-17 | 2022-11-18 | 0.11 |
| 2022-09-21 | 2022-10-12 | 0.08 |
| 2022-09-16 | 2022-09-20 | 17.48 |
Urticae vaistinė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-05-28 | 2026-06-05 | 0.01 |
| 2026-04-30 | 2026-05-25 | 0.01 |
| 2026-03-29 | 2026-04-27 | 0.01 |
| 2025-09-28 | 2025-10-26 | 0.03 |
| 2025-09-23 | 2025-09-23 | 0.03 |
| 2025-06-19 | 2025-06-19 | 7.93 |
| 2025-01-10 | 2025-01-27 | 10.93 |
| 2025-01-01 | 2025-01-09 | 0.16 |
| 2024-12-30 | 2024-12-31 | 0.04 |
| 2024-11-28 | 2024-12-28 | 0.04 |
| 2024-11-17 | 2024-11-25 | 0.04 |
| 2024-10-15 | 2024-10-16 | 0.04 |
| 2024-10-11 | 2024-10-14 | 11.81 |
| 2024-10-01 | 2024-10-10 | 0.04 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Urticae vaistine, UAB (code 133728868) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In the latest financial year, 2025, revenue amounted to €166.1K, down 14.0% year on year and 24.1% compared with 2023. The company remained loss-making, reporting a net loss of €11.5K in 2025 versus a loss of €2.4K in 2024 and a near-break-even result of €312 in 2023. The profit margin weakened to -6.9% in 2025 from -1.2% in 2024 and -0.1% in 2023. Total assets decreased from €185.3K in 2023 to €150.6K in 2025, while equity declined from €102.2K to €88.4K and liabilities from €83.2K to €62.2K. The equity ratio stood at 58.7%, debt-to-equity at 0.70, and asset turnover at 1.10x in 2025. Return on equity was -13.0% and return on assets -7.6%. Revenue per employee was €55.4K, with a loss of €3.8K per employee.